Dr. Reinier Boon (Dept. of Physiology, VUmc) received 1.1 million euros as part of the European CardioReGenix consortium (15 million euros).
The CardioReGenix consortium aims at providing novel therapies for cardiovascular disease by harnessing the latest innovations in gene therapy and recent discoveries in the field of non-coding RNAs. Experiments are aimed at developing optimal cardiac gene delivery strategies that induce robust gene expression in cardiac cells without targeting non-cardiac cells. In parallel, the consortium will identify the most promising non-coding RNAs to be used for cardiac delivery.